Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Susan D. Demo"'
Autor:
Mark K. Bennett, Frances Zhao, Jinfu Yang, Taotao Wang, Timothy F. Stanton, Eric B. Sjogren, Peter J. Shwonek, Mirna L.M. Rodriguez, Francesco Parlati, Andrew L. MacKinnon, Jim Li, Evan R. Lewis, Guy J. Laidig, Julie R. Janes, Bindu Goyal, Tania Chernov-Rogan, Lijing Chen, Jennifer B. Dennison, Susan D. Demo, Matt I. Gross
Glutamine serves as an important source of energy and building blocks for many tumor cells. The first step in glutamine utilization is its conversion to glutamate by the mitochondrial enzyme glutaminase. CB-839 is a potent, selective, and orally bioa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e71f72d571c24b467a8606b130913f41
https://doi.org/10.1158/1535-7163.c.6536490.v1
https://doi.org/10.1158/1535-7163.c.6536490.v1
Autor:
Mark K. Bennett, Frances Zhao, Jinfu Yang, Taotao Wang, Timothy F. Stanton, Eric B. Sjogren, Peter J. Shwonek, Mirna L.M. Rodriguez, Francesco Parlati, Andrew L. MacKinnon, Jim Li, Evan R. Lewis, Guy J. Laidig, Julie R. Janes, Bindu Goyal, Tania Chernov-Rogan, Lijing Chen, Jennifer B. Dennison, Susan D. Demo, Matt I. Gross
PDF - 113K, Supplementary Figure S7. Oral dosing of CB-839 results in high exposure in mouse plasma and is well tolerated in immunocompromised mice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c3ec8588e7ffe188d29168f9fdeb33a
https://doi.org/10.1158/1535-7163.22500534.v1
https://doi.org/10.1158/1535-7163.22500534.v1
Autor:
Mark K. Bennett, Frances Zhao, Jinfu Yang, Taotao Wang, Timothy F. Stanton, Eric B. Sjogren, Peter J. Shwonek, Mirna L.M. Rodriguez, Francesco Parlati, Andrew L. MacKinnon, Jim Li, Evan R. Lewis, Guy J. Laidig, Julie R. Janes, Bindu Goyal, Tania Chernov-Rogan, Lijing Chen, Jennifer B. Dennison, Susan D. Demo, Matt I. Gross
PDF - 100K, Supplementary Figure S6. The basal glutamate to glutamine ratio and the fold change in glutamine and glutamate following CB-839 treatment is greater in TNBC cells than receptor-positive cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f1ddeb0e8d6bd885689c05c47b89c90
https://doi.org/10.1158/1535-7163.22500537.v1
https://doi.org/10.1158/1535-7163.22500537.v1
Autor:
Mark K. Bennett, Frances Zhao, Jinfu Yang, Taotao Wang, Timothy F. Stanton, Eric B. Sjogren, Peter J. Shwonek, Mirna L.M. Rodriguez, Francesco Parlati, Andrew L. MacKinnon, Jim Li, Evan R. Lewis, Guy J. Laidig, Julie R. Janes, Bindu Goyal, Tania Chernov-Rogan, Lijing Chen, Jennifer B. Dennison, Susan D. Demo, Matt I. Gross
PDF - 246K, Supplementary Materials and Methods.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27a2809fd83075b7b18242c2de555985
https://doi.org/10.1158/1535-7163.22500528
https://doi.org/10.1158/1535-7163.22500528
Autor:
Mark K. Bennett, Frances Zhao, Jinfu Yang, Taotao Wang, Timothy F. Stanton, Eric B. Sjogren, Peter J. Shwonek, Mirna L.M. Rodriguez, Francesco Parlati, Andrew L. MacKinnon, Jim Li, Evan R. Lewis, Guy J. Laidig, Julie R. Janes, Bindu Goyal, Tania Chernov-Rogan, Lijing Chen, Jennifer B. Dennison, Susan D. Demo, Matt I. Gross
PDF - 126K, Supplementary Figure S3. TNBC primary tumors and cell lines have elevated glutaminase (GAC) mRNA levels.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2292352037fcafd13ccaeea4b898d9f0
https://doi.org/10.1158/1535-7163.22500546
https://doi.org/10.1158/1535-7163.22500546
Autor:
Mark K. Bennett, Frances Zhao, Jinfu Yang, Taotao Wang, Timothy F. Stanton, Eric B. Sjogren, Peter J. Shwonek, Mirna L.M. Rodriguez, Francesco Parlati, Andrew L. MacKinnon, Jim Li, Evan R. Lewis, Guy J. Laidig, Julie R. Janes, Bindu Goyal, Tania Chernov-Rogan, Lijing Chen, Jennifer B. Dennison, Susan D. Demo, Matt I. Gross
PDF - 125K, Supplementary Figure S4. Markers of glutamine utilization are increased in TNBC cell lines relative to receptor-positive cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27d41fc674aa891ef6c2532310ef88fd
https://doi.org/10.1158/1535-7163.22500543.v1
https://doi.org/10.1158/1535-7163.22500543.v1
Autor:
Mark K. Bennett, Frances Zhao, Jinfu Yang, Taotao Wang, Timothy F. Stanton, Eric B. Sjogren, Peter J. Shwonek, Mirna L.M. Rodriguez, Francesco Parlati, Andrew L. MacKinnon, Jim Li, Evan R. Lewis, Guy J. Laidig, Julie R. Janes, Bindu Goyal, Tania Chernov-Rogan, Lijing Chen, Jennifer B. Dennison, Susan D. Demo, Matt I. Gross
PDf - 136K, Supplementary Figure S1. CB-839 is a non-competitive inhibitor of rHu-GAC.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adb8d3b42109d3953173e381f10d6b83
https://doi.org/10.1158/1535-7163.22500552.v1
https://doi.org/10.1158/1535-7163.22500552.v1
Autor:
Mark K. Bennett, Frances Zhao, Jinfu Yang, Taotao Wang, Timothy F. Stanton, Eric B. Sjogren, Peter J. Shwonek, Mirna L.M. Rodriguez, Francesco Parlati, Andrew L. MacKinnon, Jim Li, Evan R. Lewis, Guy J. Laidig, Julie R. Janes, Bindu Goyal, Tania Chernov-Rogan, Lijing Chen, Jennifer B. Dennison, Susan D. Demo, Matt I. Gross
PDF - 189K, Supplementary Figure S2. CB-839 has potent anti-proliferative activity in TNBC cells that is associated with selective impairment of glutamine utilization.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57bb8fab0e810a6a7119b446c2e72057
https://doi.org/10.1158/1535-7163.22500549.v1
https://doi.org/10.1158/1535-7163.22500549.v1
Autor:
Mark K. Bennett, Frances Zhao, Jinfu Yang, Taotao Wang, Timothy F. Stanton, Eric B. Sjogren, Peter J. Shwonek, Mirna L.M. Rodriguez, Francesco Parlati, Andrew L. MacKinnon, Jim Li, Evan R. Lewis, Guy J. Laidig, Julie R. Janes, Bindu Goyal, Tania Chernov-Rogan, Lijing Chen, Jennifer B. Dennison, Susan D. Demo, Matt I. Gross
PDF - 85K, Supplementary Figure S5. Induction of apoptotic cell death by CB-839.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::417ab303428d2644d6537eaa44718298
https://doi.org/10.1158/1535-7163.22500540
https://doi.org/10.1158/1535-7163.22500540
Autor:
Mark K. Bennett, Christopher J. Molineaux, Tina M. Woo, Marcy K. Vallone, Congcong M. Sun, Mark S. Smyth, Kevin D. Shenk, Francesco Parlati, Evan R. Lewis, Guy J. Laidig, Jing Jiang, Mark N. Ho, Maya Dajee, Tonia J. Buchholz, Monette A. Aujay, Christopher J. Kirk, Susan D. Demo
Supplementary Figure 1 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a101c8883eaf41acd7d210a2605a14a
https://doi.org/10.1158/0008-5472.22367433.v1
https://doi.org/10.1158/0008-5472.22367433.v1